Aug 2026· Current Oncology· Vol 33, pp. 483· 0 citations· 28 references
Medicine
TL;DR
Current evidence on inflammatory biomarkers, including interleukin-6, tumor necrosis factor-alpha, C-reactive protein, the neutrophil-to-lymphocyte ratio, and serum albumin are synthesized to clarify their clinical utility and to support efforts toward standardized assessment, early recognition, and improved monitoring of cancer-associated cachexia.
Abstract
Simple Summary Cancer-associated cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and poor nutritional intake secondary to anorexia, affecting up to 80% of patients with advanced cancer. Despite its profound impact on survival and quality of life, inconsistent diagnostic criteria and heterogeneity in measurement across research studies limit its translation into routine clinical practice. Inflammatory biomarkers, including interleukin-6, tumor necrosis factor-alpha, C-reactive protein, the neutrophil-to-lymphocyte ratio, and serum albumin, have been widely investigated for their ability to reflect the presence, severity, and progression of cachexia. This review aimed to synthesize current evidence on these key biomarkers to clarify their clinical utility and to support efforts toward standardized assessment, early recognition, and improved monitoring of cancer-associated cachexia.
Cancer cachexia is a multifactorial metabolic syndrome characterized by progressive skeletal muscle loss, affecting 30–60% of patients with advanced renal cell carcinoma (RCC). It significantly impacts treatment tolerance, quality of life, and prognosis, yet its diagnosis and management remain challenging due to fragme...
Yu-Shuang Cui, Yu-Dong Cao, Chen Lin et al.· International Journal of Mol...· 0 citations
Cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and muscle wasting, affecting over 80% of patients with pancreatic cancer. It decreases treatment tolerance, quality of life, and survival. Yet, despite its well-recognized detrimental impact, cachexia remains underdiagnosed and...
A personalized medicine approach integrating REE, given its growing evidence for prognostic and clinical utility, with nutritional support, adapted physical activity, and targeted anti-cachexia therapies, all coordinated by the oncologist, represents a promising path forward.
Pamela Funk Debleds, K. Furness, Vivian V. Nguyen et al.· Clinical Nutrition ESPEN· 0 citations
Chronic inflammation is a universally acknowledged characteristic of cancer, playing the role of a vital catalyst in cancer initiation and progression, and a chief predictor of the success or failure of cancer therapies. About 20% of all cancer cases are associated with states of chronic inflammation, and an even great...
Pritam Kayal, Ramit Rahaman, A. Ghosh et al.· International Immunopharmaco...· 0 citations
Simple Summary Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Although anti-PD-1 immunotherapy has significantly improved treatment outcomes for patients with advanced disease, a substantial portion of individuals do not respond, and reliable pretreatment tools to predict succes...
Tara Coreanu, Ido Amir, N. Edri et al.· Cancers· 0 citations
Sarcopenia is defined as a loss of muscle mass and strength. It represents a frequent and multifactorial complication in patients with gastrointestinal cancers, resulting from the combined effects of malnutrition, chronic inflammation, metabolic alterations, and reduced physical activity level. Its assessment relies on...
Géraldine M. Camilleri, Eléa Janvier, F. Pigneur et al.· Bulletin du Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
